Valuation: Precipio Inc

Market Cap 4.25Cr 3.72Cr 3.43Cr 3.17Cr 6.01Cr 405.72Cr 6.12Cr 41Cr 16Cr 199.87Cr 16Cr 16Cr 687.11Cr P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 4.35Cr 3.81Cr 3.51Cr 3.24Cr 6.16Cr 415.27Cr 6.26Cr 42Cr 16Cr 204.58Cr 16Cr 16Cr 703.29Cr EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.41%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 01/06/2017
Chief Executive Officer 54 28/06/2017
Director TitleAgeSince
Director/Board Member 54 28/06/2017
Director/Board Member 78 26/09/2017
Director/Board Member 67 08/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 4.25Cr
+3.73%+6.80%+9.75%-22.36% 1.73TCr
+3.87%-5.71%+14.03%+89.94% 168.39Cr
+4.76%+0.11%-39.78%-78.85% 124.58Cr
-2.75%-6.73%-32.28%+29.11% 106.09Cr
+2.92%-2.22%-29.25%-54.48% 63Cr
+3.91%-4.74%-39.86%-57.02% 55Cr
+2.60%+4.15%+35.25%-52.31% 47Cr
+1.13%-0.48%-54.86%-58.92% 38Cr
+2.67%-5.46%-24.37%-24.54% 34Cr
Average +4.29%-0.88%-17.93%-25.49% 262.71Cr
Weighted average by Cap. +3.44%+4.44%+2.33%-17.90%

Financials

2024 2025
Net sales 1.85Cr 1.62Cr 1.5Cr 1.38Cr 2.62Cr 176.75Cr 2.66Cr 18Cr 7.02Cr 87Cr 6.96Cr 6.81Cr 299.33Cr 2.4Cr 2.1Cr 1.94Cr 1.79Cr 3.4Cr 229.37Cr 3.46Cr 23Cr 9.1Cr 112.99Cr 9.03Cr 8.83Cr 388.44Cr
Net income -42.9L -37.52L -34.61L -31.97L -60.66L -41Cr -61.68L -4.14Cr -1.62Cr -20Cr -1.61Cr -1.58Cr -69Cr -4L -3L -3L -3L -5L -3.46Cr -5L -34.99L -13.74L -1.71Cr -13.63L -13.33L -5.86Cr
Net Debt -1L -1L -1L -1L -2L -1.3Cr -2L -13.11L -5L -63.9L -5L -5L -2.2Cr 10.02L 9L 8L 7L 14.17L 9.56Cr 14.41L 96.59L 37.93L 4.71Cr 37.62L 36.8L 16Cr
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-